Overall Fundamental outlook

*LAURUSLABS makes the list of companies with the worst technicals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Investors may react cautiously to news that LAURUSLABS's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 57.245396
debtToEquity 44.831000
earningsGrowth 1.719000
revenueGrowth 0.257000
grossMargins 0.570230
operatingMargins 0.202210
trailingEps 15.650000
forwardEps 17.755140

With a forward PE that's too high, LAURUSLABS may face limited future price growth and an increased risk of correction. It's important for investors to evaluate this alongside other fundamental parameters to get a fuller picture of the stock's valuation.
LAURUSLABS's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
Positive gross and operating margins for Laurus Labs Limited highlight the company's profitability. These metrics reflect Laurus Labs Limited's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
Laurus Labs Limited's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting Laurus Labs Limited to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have gradually risen, indicating growing confidence in the company's prospects. This upward trend suggests that analysts expect LAURUSLABS to continue performing well in the future.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Laurus Labs Limited has faced a sell bias from analysts recently, indicating that caution is advised. Investors should expand their focus to a broader set of market indicators when making decisions, ensuring a well-rounded approach rather than acting solely on one piece of analysis.